BioTelemetry Company Profile (NASDAQ:BEAT)

About BioTelemetry (NASDAQ:BEAT)

BioTelemetry logoBioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BEAT
  • CUSIP: N/A
  • Web: www.gobio.com
Capitalization:
  • Market Cap: $1.00802 billion
  • Outstanding Shares: 32,360,000
Average Prices:
  • 50 Day Moving Avg: $33.36
  • 200 Day Moving Avg: $32.36
  • 52 Week Range: $15.25 - $39.20
P/E:
  • Trailing P/E Ratio: 20.54
  • Foreward P/E Ratio: 20.96
  • P/E Growth: 1.43
Sales & Book Value:
  • Annual Revenue: $211.19 million
  • Price / Sales: 4.69
  • Book Value: $5.11 per share
  • Price / Book: 5.99
Profitability:
  • EBITDA: $41.34 million
  • Net Margins: 21.03%
  • Return on Equity: 18.75%
  • Return on Assets: 12.70%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.03%
  • Quick Ratio: 1.91%
Misc:
  • Average Volume: 507,448 shs.
  • Beta: 0.69
  • Short Ratio: 5.72
 

Frequently Asked Questions for BioTelemetry (NASDAQ:BEAT)

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) announced its earnings results on Tuesday, August, 8th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.02. The firm had revenue of $58.10 million for the quarter, compared to the consensus estimate of $58.39 million. BioTelemetry had a return on equity of 18.75% and a net margin of 21.03%. The company's revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS. View BioTelemetry's Earnings History.

Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?

7 brokerages have issued 12-month target prices for BioTelemetry's shares. Their forecasts range from $40.00 to $50.00. On average, they expect BioTelemetry's stock price to reach $45.75 in the next twelve months. View Analyst Ratings for BioTelemetry.

Who are some of BioTelemetry's key competitors?

Who owns BioTelemetry stock?

BioTelemetry's stock is owned by many different of institutional and retail investors. Top institutional investors include Summit Creek Advisors LLC (1.05%), Strs Ohio (0.44%), Curbstone Financial Management Corp (0.07%), LS Investment Advisors LLC (0.03%) and Winslow Evans & Crocker Inc. (0.01%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Who sold BioTelemetry stock? Who is selling BioTelemetry stock?

BioTelemetry's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC. Company insiders that have sold BioTelemetry stock in the last year include Fred Broadway, George Hrenko and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Who bought BioTelemetry stock? Who is buying BioTelemetry stock?

BioTelemetry's stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Curbstone Financial Management Corp, Winslow Evans & Crocker Inc. and LS Investment Advisors LLC. View Insider Buying and Selling for BioTelemetry.

How do I buy BioTelemetry stock?

Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BioTelemetry stock can currently be purchased for approximately $30.60.


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $45.75 (49.51% upside)
Consensus Price Target History for BioTelemetry (NASDAQ:BEAT)
Price Target History for BioTelemetry (NASDAQ:BEAT)
Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017SunTrust Banks, Inc.Initiated CoverageBuyN/AView Rating Details
9/15/2017Off Wall StreetInitiated CoverageSellMediumView Rating Details
8/10/2017SidotiReiterated RatingBuy$42.00 -> $49.00LowView Rating Details
8/9/2017Dougherty & CoBoost Price TargetBuy$37.00 -> $40.00HighView Rating Details
7/19/2017Benchmark Co.Boost Price TargetBuy -> Buy$38.00 -> $44.00LowView Rating Details
7/14/2017Lake Street CapitalReiterated RatingBuy$35.00 -> $50.00HighView Rating Details
12/13/2016GabelliReiterated RatingBuyN/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for BioTelemetry (NASDAQ:BEAT)
Earnings by Quarter for BioTelemetry (NASDAQ:BEAT)
Earnings History by Quarter for BioTelemetry (NASDAQ BEAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017$0.21$0.23$58.39 million$58.10 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.14$0.16$55.11 million$55.88 millionViewListenView Earnings Details
2/22/2017Q4 2016$0.18$0.23$53.75 million$53.96 millionViewListenView Earnings Details
11/2/2016Q316$0.18$0.21$52.92 million$53.10 millionViewN/AView Earnings Details
8/2/2016Q2$0.17$0.20$50.27 million$52.68 millionViewListenView Earnings Details
4/26/2016Q1$0.10$0.20$46.54 million$48.60 millionViewListenView Earnings Details
2/17/2016Q415$0.11$0.15$45.89 million$46.70 millionViewListenView Earnings Details
11/9/2015Q3$0.11$0.13$46.05 million$43.49 millionViewN/AView Earnings Details
8/6/2015Q2$0.09$0.12$45.75 million$44.81 millionViewListenView Earnings Details
5/6/2015Q115$0.02$0.06$43.80 million$43.40 millionViewListenView Earnings Details
2/19/2015Q414$0.06$0.05$43.40 million$43.70 millionViewListenView Earnings Details
10/30/2014Q214$0.01$0.06$42.00 million$43.00 millionViewListenView Earnings Details
7/31/2014Q114$0.01$0.02$40.95 million$42.70 millionViewListenView Earnings Details
5/6/2014Q413($0.02)($0.04)$38.40 million$37.16 millionViewListenView Earnings Details
2/26/2014Q313($0.04)$0.05$32.26 million$33.10 millionViewListenView Earnings Details
11/5/2013($0.05)($0.12)$32.79 million$31.90 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.02$27.50 million$32.10 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.09)$26.80 million$30.00 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.08)$26.49 million$27.00 millionViewN/AView Earnings Details
8/8/2012($0.04)($0.01)ViewN/AView Earnings Details
5/8/2012($0.12)($0.10)ViewN/AView Earnings Details
2/22/2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2011($0.09)($0.21)ViewN/AView Earnings Details
8/8/2011($0.06)($0.05)ViewN/AView Earnings Details
5/3/2011($0.15)($0.02)ViewN/AView Earnings Details
2/17/2011($0.16)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioTelemetry (NASDAQ:BEAT)
2017 EPS Consensus Estimate: $0.86
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.20$0.20$0.20
Q2 20171$0.20$0.20$0.20
Q3 20172$0.19$0.28$0.24
Q4 20171$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioTelemetry (NASDAQ:BEAT)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 77.40%
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Robert J. RubinDirectorSell15,000$28.14$422,100.00View SEC Filing  
3/20/2017Fred BroadwaySVPSell3,429$26.90$92,240.10View SEC Filing  
2/27/2017George HrenkoSVPSell126,043$25.95$3,270,815.85View SEC Filing  
2/21/2017Fred BroadwaySVPSell8,070$24.81$200,216.70View SEC Filing  
9/19/2016George HrenkoSVPSell1,061$18.50$19,628.50View SEC Filing  
9/13/2016Heather C GetzCFOSell5,866$18.23$106,937.18View SEC Filing  
9/13/2016Joseph H CapperInsiderSell26,847$18.23$489,420.81View SEC Filing  
9/13/2016Peter FerolaGeneral CounselSell4,352$18.23$79,336.96View SEC Filing  
9/9/2016Fred BroadwaySVPSell3,146$17.84$56,124.64View SEC Filing  
9/8/2016George HrenkoSVPSell3,491$18.06$63,047.46View SEC Filing  
9/8/2016Heather C GetzCFOSell2,979$18.10$53,919.90View SEC Filing  
9/8/2016Joseph H CapperInsiderSell13,632$18.10$246,739.20View SEC Filing  
9/8/2016Peter FerolaGeneral CounselSell2,210$18.10$40,001.00View SEC Filing  
9/7/2016Daniel WisniewskiSVPSell9,225$18.51$170,754.75View SEC Filing  
9/7/2016Heather C GetzCFOSell18,945$18.52$350,861.40View SEC Filing  
9/7/2016Joseph H CapperInsiderSell86,681$18.52$1,605,332.12View SEC Filing  
9/7/2016Peter FerolaGeneral CounselSell14,053$18.52$260,261.56View SEC Filing  
9/6/2016Fred BroadwaySVPSell4,662$18.28$85,221.36View SEC Filing  
9/6/2016Heather C GetzCFOSell6,686$18.29$122,286.94View SEC Filing  
9/6/2016Joseph H CapperCEOSell30,595$18.29$559,582.55View SEC Filing  
9/6/2016Peter FerolaGeneral CounselSell4,960$18.29$90,718.40View SEC Filing  
9/2/2016Fred BroadwaySVPSell4,466$18.75$83,737.50View SEC Filing  
9/2/2016Heather C GetzCFOSell6,547$18.75$122,756.25View SEC Filing  
9/2/2016Joseph H CapperCEOSell29,953$18.75$561,618.75View SEC Filing  
9/2/2016Peter FerolaGeneral CounselSell4,856$18.75$91,050.00View SEC Filing  
9/1/2016Fred BroadwaySVPSell7,525$19.25$144,856.25View SEC Filing  
9/1/2016Heather C GetzCFOSell10,408$18.59$193,484.72View SEC Filing  
9/1/2016Joseph H CapperInsiderSell47,622$18.59$885,292.98View SEC Filing  
9/1/2016Peter FerolaGeneral CounselSell7,722$18.59$143,551.98View SEC Filing  
8/30/2016Fred BroadwaySVPSell12,121$19.07$231,147.47View SEC Filing  
8/30/2016Heather C GetzCFOSell17,482$19.07$333,381.74View SEC Filing  
8/30/2016Joseph H CapperInsiderSell79,986$19.07$1,525,333.02View SEC Filing  
8/30/2016Peter FerolaGeneral CounselSell12,970$19.07$247,337.90View SEC Filing  
8/25/2016Fred BroadwaySVPSell5,877$19.16$112,603.32View SEC Filing  
8/25/2016Heather C GetzCFOSell8,477$19.16$162,419.32View SEC Filing  
8/25/2016Joseph H CapperInsiderSell38,785$19.16$743,120.60View SEC Filing  
8/25/2016Peter FerolaGeneral CounselSell6,289$19.16$120,497.24View SEC Filing  
8/24/2016George HrenkoSVPSell7,473$20.11$150,282.03View SEC Filing  
8/24/2016Heather C GetzCFOSell8,778$20.11$176,525.58View SEC Filing  
8/24/2016Joseph H CapperCEOSell40,160$20.11$807,617.60View SEC Filing  
8/24/2016Peter FerolaGeneral CounselSell6,512$20.11$130,956.32View SEC Filing  
8/23/2016George HrenkoSVPSell3,165$20.67$65,420.55View SEC Filing  
8/23/2016Heather C GetzCFOSell3,717$20.67$76,830.39View SEC Filing  
8/23/2016Joseph H CapperCEOSell17,008$20.67$351,555.36View SEC Filing  
8/23/2016Peter FerolaGeneral CounselSell2,758$20.67$57,007.86View SEC Filing  
8/22/2016George HrenkoSVPSell4,149$20.85$86,506.65View SEC Filing  
8/22/2016Heather C GetzCFOSell4,874$20.85$101,622.90View SEC Filing  
8/22/2016Joseph H CapperCEOSell22,298$20.85$464,913.30View SEC Filing  
8/22/2016Peter FerolaGeneral CounselSell3,616$20.85$75,393.60View SEC Filing  
8/19/2016Daniel WisniewskiSVPSell9,025$20.96$189,164.00View SEC Filing  
8/19/2016Heather C GetzCFOSell9,026$20.96$189,184.96View SEC Filing  
8/19/2016Joseph H CapperInsiderSell9,049$20.96$189,667.04View SEC Filing  
8/19/2016Peter FerolaGeneral CounselSell9,035$20.96$189,373.60View SEC Filing  
5/9/2014Ronald AhrensDirectorBuy6,000$7.37$44,220.00View SEC Filing  
11/12/2013Ronald AhrensDirectorBuy5,000$11.73$58,650.00View SEC Filing  
11/12/2012Ronald A AhrensDirectorBuy15,000$2.22$33,300.00View SEC Filing  
9/5/2012Joseph H CapperCEOBuy23,540$2.25$52,965.00View SEC Filing  
8/31/2012Joseph H CapperCEOBuy2,600$2.28$5,928.00View SEC Filing  
8/29/2012Joseph H CapperCEOBuy10,800$2.30$24,840.00View SEC Filing  
8/28/2012Joseph H CapperCEOBuy1,300$2.19$2,847.00View SEC Filing  
8/27/2012Joseph H CapperCEOBuy1,600$2.12$3,392.00View SEC Filing  
8/23/2012Joseph H CapperCEOBuy9,600$2.08$19,968.00View SEC Filing  
8/20/2012Joseph H CapperCEOBuy14,160$1.97$27,895.20View SEC Filing  
8/17/2012Joseph H CapperCEOBuy9,800$2.10$20,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioTelemetry (NASDAQ:BEAT)
Latest Headlines for BioTelemetry (NASDAQ:BEAT)
Source:
Loading headlines, please wait.

Social

Chart

BioTelemetry (BEAT) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.